MAM
AKBA icon

Meeder Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Meeder Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-270
Closed -$1K – 2496
2021
Q1 		$1K Buy
+270
New +$973 ﹤0.01% 2166
2020
Q3 		– Sell
-10,276
Closed -$139K – 2151
2020
Q2 		$139K Buy
10,276
+4,885
+91% +$50.5K 0.01% 685
2020
Q1 		$42K Buy
5,391
+650
+14% +$5.06K ﹤0.01% 972
2019
Q4 		$30K Buy
4,741
+3,308
+231% +$15.7K ﹤0.01% 1208
2019
Q3 		$6K Sell
1,433
-2,281
-61% -$9.78K ﹤0.01% 1685
2019
Q2 		$18K Buy
+3,714
New +$21.1K ﹤0.01% 1267
2019
Q1 		– Sell
-3,308
Closed -$19K – 1690
2018
Q4 		$19K Buy
3,308
+2,504
+311% +$19.6K ﹤0.01% 1074
2018
Q3 		$7K Sell
804
-15
-2% -$134 ﹤0.01% 1234
2018
Q2 		$8.17K Buy
819
+739
+924% +$7.4K ﹤0.01% 1160
2018
Q1 		$1K Sell
80
-140
-64% -$1.96K ﹤0.01% 1439
2017
Q4 		$3K Buy
+220
New +$3.65K ﹤0.01% 1414
2017
Q3 		– Sell
-317
Closed -$5K – 1618
2017
Q2 		$5K Sell
317
-357
-53% -$4.53K ﹤0.01% 1180
2017
Q1 		$6K Buy
674
+452
+204% +$4.41K ﹤0.01% 989
2016
Q4 		$2K Buy
+222
New +$1.91K ﹤0.01% 927

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Meeder Asset Management's AKBA Position: Q2 2021 in Review

Meeder Asset Management sold out of Akebia Therapeutics (AKBA) in Q2 2021, closing a stake of 270 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in AKBA in Q4 2016 and held it in 14 quarters. The position peaked at $139K in Q2 2020. 139 funds tracked by Wall St. Rank hold AKBA as of Q2 2021.

  • Meeder Asset Management reported no remaining Akebia Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Meeder Asset Management sold 270 Akebia Therapeutics shares in Q2 2021, an estimated $1K.
  • Meeder Asset Management first reported a position in Akebia Therapeutics in Q4 2016 and held it in 14 quarters.
  • Meeder Asset Management's Akebia Therapeutics position peaked at $139K in Q2 2020.
  • 139 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2021.

Based on Meeder Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.